Extended-release opioids for the management of chronic non-malignant pain

Expert Opinion on Drug Delivery

Volumn 3, Issue 4, 2006, Pages 489-497

  Sloan, Paul ^a   Babul, Najib ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b TheraQuest Biosciences   (United States)

Author keywords

Abuse deterrence; Chronic pain; Extended release; Neuropathic pain; Opioids; Sustained release

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ANIMAL; CHRONIC DISEASE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; HUMAN; PAIN; REVIEW; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; HUMANS; PAIN; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34547852667     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.4.489     Document Type: Review

References (53)

1. REID C, DAVIES A: The World Health Organization three-step analgesic ladder comes of age. Palliat. Med. (2004) 18:175-176. (Pubitemid 38771656)
2. TWYCROSS RG. Clinical experience with diamorphine in advanced malignant disease. Int. J. Clin. Pharmacol. (1974) 7:1844-1898.
3. MELZACK R, OFIESH JG, MOUNT BM. The Brompton mixture: effects on pain in cancer patients. Can. Med. Assoc. J. (1976) 115:125-129.
4. THIRLWELL MP, SLOAN PA, MAROUN JA et al.: Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer (1989) 63:2275-2283. (Pubitemid 19141073)
5. HAYS H, HAGEN N, THIRLWELL M et al.: Comparative clinical efficacy and safety of immediate and controlled release hydromorphone formulations in severe cancer pain. Cancer (1994) 74:1808-1816. (Pubitemid 24301837)
6. HAGEN N, BABUL N: Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer (1997) 79:1428-1437. (Pubitemid 27143251)
7. BABUL N, PROVENCHER L, LABERGE F, HARSANYI Z, MOULIN D: Comparative efficacy and safety of controlled release morphine suppositories and tablets in cancer pain. J. Clin. Pharm. (1998) 38:74-81. (Pubitemid 28086727)
8. BOLEN J, HELMICK CG, SACKS JJ, LANGMAID G: Prevalence of self-reported arthritis or chronic joint symptoms among adults - United States, 2001. MMWR Morb. Mortal. Wkly Rep. (2002) 51(42):948-950.
9. COLUZZI F, PAPPAGALLO M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. (2005) 71:425-433. (Pubitemid 43932967)
10. KATZ N. Methodological issues in clinical trials of opioids for chronic pain. Neurology (2005) 65(12 Suppl. 4):S32-S49. (Pubitemid 43755490)
11. KALSO E, EDWARDS JE, MOORE RA, MCQUAY HJ: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain (2004) 112:372-380. •• Recent meta-analysis of placebo-controlled, double-blind trials of opioids for chronic pain. (Pubitemid 39550738)
12. MARKENSON JA, CROFT J, ZHANG PG, RICHARDS P: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin. J. Pain (2005) 21(6):524-535. (Pubitemid 41527742)
13. GOURLAY GK: Advances in opioid pharmacology. Supp. Care Cancer (2005) 13:153-159. (Pubitemid 40468961)
14. HANKS GW, REID C: Contribution to variability in response to opioids. Supp. Care Cancer (2005) 13:145-152. •• Excellent review describing pharmacokinetic and pharmacodynamic reasons for patient-variable response to clinical opioid therapy.
15. HEISKANEN T, OLKKOLA KT, KALSO E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacokinetics of oxycodone. Clin. Pharmacol. Ther. (1998) 64:603-611. (Pubitemid 29011380)
16. MURRAY A, HAGEN NA: Hydromorphone. J. Pain Symptom Manage. (2005) 29:S57-S66.
17. GUAY DRP, AWNI WM, HALSTENSON CE et al.: Pharmacokinetics of codeine after single and multiple oral dose administration to normal volunteers. J. Clin. Pharmacol. (1987) 27:983-987. (Pubitemid 18259045)
18. SINDRUP SH, ARENDT-NIELSEN L, BROSEN K et al.: The effect of quinidine on the analgesic effect of codeine. Eur. J. Clin. Pharmacol. (1992) 42:587-591.
19. SINDRUP SH, POULSEN L, BROSEN K, ARENDT-NIELSEN L, GRAM LF: Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain (1993) 53:335-359. (Pubitemid 23172381)
20. SLOAN PA, SLATKIN NE, AHDIEH H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Supp. Care Cancer (2005) 13:57-65. • Large clinical trial demonstrating the efficacy of ER oxymorphone for treatment of cancer pain.
21. ADAMS M, PIENIASZEK HJ Jr, GAMMAITONI AR, AHDIEH H: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin. Pharm. (2005) 45:337-345. (Pubitemid 40490430)
22. DRIESSEN B, REIMANN W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydoxytryptamine in the rat brain in vitro. Br. J. Pharm. (1992) 105:147-151.
23. LOTSCH J: Opioid metabolites. J. Pain Symptom Manage. (2005) 29:S10-S24. (Pubitemid 40720243)
24. WILSEY BL, FISHMAN SM: Minor and short-acting opioids. In: Essentials of Pain Medicine and Reg. Anesth. HT Benzon, SN Raja, RE Molloy, SS Liu, SM Fishman (Eds), Elsevier Churchill Livingstone, Philadelphia, PA, USA (2005):106-112.
25. WEBB JA, ROSTAMI-HODJEGAN A, ABDUL-MANAP R, HOFMANN U, MIKUS G, KAMALI F: Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br. J. Clin. Pharmacol. (2001) 52(1):35-43. (Pubitemid 32862767)
26. STAMBAUGH JE, REDER RF, STAMBAUGH MD, STAMBAUGH H, DAVIS M. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J. Clin. Pharmacol. (2001) 41:500-506. (Pubitemid 32381867)
27. BROOMHEAD A, KERR R, TESTER W et al.: Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J. Pain Symptom Manage. (1997) 14:63-73. (Pubitemid 27323494)
28. MOULIN DE, IEZZI A, AMIREH R, SHARPE WK, BOYD D, MERSKEY H: Randomised trial of oral morphine for chronic non-cancer pain. Lancet (1996) 347(8995):143-147. •• Key early study using randomised double-blind and placebo-controlled methods to demonstrate pain relief of morphine for chronic pain patients.
29. CALDWELL JR, RAPOPORT RJ, DAVIS JC et al.: Efficacy and safety of once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J. Pain Symptom Manage. (2002) 23:278-291. • Large double-blind randomised trial demonstrating pain relief from osteoarthritis using ER morphine.
30. ALLEN L, RIONARZ U, SIMPSON K, SLANPPENDEL R: Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine (2005) 30:2484-2490. (Pubitemid 41669082)
31. WATSON CP, BABUL N: Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology (1998) 50:1837-1841. (Pubitemid 28283261)
32. GIMBEL JS, RICHARDS P, PORTENOY RK: Controlled-release oxycodone for pain in diabetic neuropathy. Neurology (2003) 60:927-934.
33. WATSON CPN, MOULIN DE, WATT-WATSON J, GORDON A, EISENHOFFER J: Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain (2003) 105:71-78. • Randomised clinical trial demonstrating pain relief and improved physical function with use of ER opioids for patients with neuropathic pain. (Pubitemid 37162475)
34. MARKENSON JA, CROFT J, ZHANG PG, RICHARDS P: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin. J. Pain (2005) 21:524-535. • Large placebo-controlled clinical trial demonstrating effective pain relief with ER oxycodone as well as improved patient functioning.
35. PALANGIO M, NORTHFELT DW, PORTENOY RK et al.: Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or non-malignant pain. J. Pain Symptom Manage. (2002) 23:355-368. (Pubitemid 34463005)
36. GROSSET AB, ROBERTS MS, WOODSON ME et al.: Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials. J. Pain Symptom Manage. (2005) 29:584-594. (Pubitemid 40826481)
37. PELOSO PM, BELLAMY N, BENSEN W et al.: Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J. Rheumatol. (2000) 27:764-771. (Pubitemid 30151360)
38. MATSUMOTO AK, BABUL N, AHDIEH H: Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled Phase III trial. Pain Med. (2005) 6:357-366. • Very recent clinical trial demonstrating improved pain relief and physical function with ER oxymorphone in patients with chronic pain. (Pubitemid 41727333)
39. HALE ME, DVERGSTEN C, GIMBEL J: Efficacy and safety of oxymorphone extended-release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled Phase III study. J. Pain (2005) 6:21-28. (Pubitemid 40051998)
40. BABUL N, NOVECK R, CHIPMAN H, ROTH H, GANA T, ALBERT K: Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J. Pain Symptom Manage. (2004) 28:59-71. (Pubitemid 38829673)
41. MALONNE H, COFFINER M, SONET B, SERENO A, VANDERBIST F: Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. (2004) 26:1774-1782. • Large recent clinical trial demonstrating efficacy of ER tramadol for the treatment of chronic pain. (Pubitemid 40089490)
42. BERGER A, HOFFMAN DL, GOODMAN S, DELEA TE, SEIFELDIN R, OSTER G: Therapy switching patients receiving long-acting opioids. Ann. Pharmacother. (2004) 38:389-395. • Large review of patients started on opioids and the incidence and outcome of opioid rotation.
43. REISSIG JE, RYBARCZYK AM: Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann. Pharmacother. (2005) 39:727-731. (Pubitemid 40396629)
44. FISHBAIN DA, CUTLER RB, ROSOMOFF HL, ROSOMOFF RS: Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J. Pain Symptom Manage. (2003) 25:559-577. • Excellent review of available literature showing little reason to not allow patients on chronic opioids to drive.
45. PORTENOY RK, COYLE N: Controversies in the long-term management of analgesic therapy in patients with advanced cancer. J. Pain Symptom Manage. (1990) 5:307-319. (Pubitemid 20368685)
46. PORTENOY RK: Opioid therapy for chronic non-malignant pain: a review of the critical issues. J. Pain Symptom Manage. (1996) 11:203-217. (Pubitemid 26102522)
47. BENNETT DS, CARR DB: Opiophobia as a barrier to the treatment of pain. J. Pain Palliat. Care Pharmacother. (2002) 16:105-109. (Pubitemid 35408276)
48. Palladone for chronic pain. Med. Lett. Drugs Ther. (2005) 47(1207):21-23.
49. MURRAY S, WOOLTORTON E: Alcohol-associated rapid release of a long-acting opioid. CMAJ. (2005) 173:756. (Pubitemid 41428510)
50. www.ampainsoc.org/advocacy/opioids2.htm Definitions related to the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine (2001).
51. www.fda.gov/cder/drug/infosheets/HCP/ hydromorphoneHCP.pdf FDA Alert: alcohol-Palladone interaction (2005).
52. www.fda.gov/cder/drug/infopage/palladone/default.htm Palladone ER capsules (hydromorphone) information (2005).
53. www.fda.gov/medwatch/safety/2005/avinza-dhcp-letter-Oct2005.pdf Letter from Ligand Pharmaceuticals, Inc. with information regarding AVINZA® (morphine sulfate ER capsules) (2005).